Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GENinCode UK Ltd. ( (GB:GENI) ) has issued an announcement.
GENinCode Plc reported a 15% increase in revenue to £1.6m for the first half of 2025, driven by growth in the UK, EU, and US markets. Despite maintaining a steady gross profit margin of 53%, the company faced losses of £2.4m. The company is progressing with FDA De Novo discussions and advancing collaboration talks for test distribution in the US and EU. New clinical data on their CARDIO inCode-Score was presented at major cardiology conferences, highlighting its significance in cholesterol risk modulation for coronary heart disease.
The most recent analyst rating on (GB:GENI) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.
Spark’s Take on GB:GENI Stock
According to Spark, TipRanks’ AI Analyst, GB:GENI is a Neutral.
GENinCode UK Ltd. faces significant financial challenges, with persistent losses and cash flow issues being the most critical factors. The technical analysis suggests a bearish trend, while the valuation is hampered by negative earnings. However, recent corporate events show positive strategic developments, which could support future growth.
To see Spark’s full report on GB:GENI stock, click here.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in the prevention of cardiovascular disease and surveillance testing for ovarian cancer. It operates in the UK, Europe, and the United States, providing globally leading diagnostics and risk assessment for precision medicine treatment and preventive care. The company uses in vitro diagnostic molecular tests, clinical algorithms, and AI bioinformatics to advance patient risk assessment.
Average Trading Volume: 429,749
Technical Sentiment Signal: Sell
Current Market Cap: £4.02M
Learn more about GENI stock on TipRanks’ Stock Analysis page.